We read with interest a recent article in Tumor Biology [1] , in which Meade et al. helpfully compared the mucosal tolerability of several concurrent chemo-radiation schedules used to treat head-and-neck squamous cell carcinoma (HNSCC) with the predictions of three tolerance models developed for radiation-only schedules [2] [3] [4] . Meade et al. added estimates of the radiation-equivalent biologically effective doses for cell kill contributed by the chemotherapy components of the various schedules (BED ck-chemo ) to the BEDs contributed by radiation alone (BED ck-RT ), thereby generating total BED values (BED ck-tot ) which were compared with durationspecific tolerance ceilings specified by the three models. The study concluded that this BED-summation approach was useful but that the tolerance ceilings may need further adjustment in the chemo-radiation setting and noted that an accelerated schedule used in the RTOG 0129 study [5] was predicted to be intolerable by all three models, despite current indications that it may be tolerable.
To the Editor,
We read with interest a recent article in Tumor Biology [1] , in which Meade et al. helpfully compared the mucosal tolerability of several concurrent chemo-radiation schedules used to treat head-and-neck squamous cell carcinoma (HNSCC) with the predictions of three tolerance models developed for radiation-only schedules [2] [3] [4] . Meade et al. added estimates of the radiation-equivalent biologically effective doses for cell kill contributed by the chemotherapy components of the various schedules (BED ck-chemo ) to the BEDs contributed by radiation alone (BED ck-RT ), thereby generating total BED values (BED ck-tot ) which were compared with durationspecific tolerance ceilings specified by the three models. The study concluded that this BED-summation approach was useful but that the tolerance ceilings may need further adjustment in the chemo-radiation setting and noted that an accelerated schedule used in the RTOG 0129 study [5] was predicted to be intolerable by all three models, despite current indications that it may be tolerable.
We were a little surprised that our tolerance ceiling model (denoted by Meade et al. as Fen BED ck ) did not correctly predict the tolerance of the accelerated RTOG 0129 schedule, since we had fitted the model to a large radiation-only dataset using discriminant analysis [2] , and Meade and colleagues very carefully obtained a BED ck-tot value for the delivered schedule, by adding to its radiation-only BED ck-RT dose a BED ck-chemo value of 2.9 Gy 10 individually estimated for the chemotherapy regimen used in the schedule.
In this context two observations should be made about our model. Firstly, it is most simply written as
in which the sine function argument is specified in radians, and T is defined as the total radiotherapy duration including both the first and last days of treatment [2] , which is 1 day longer than the definition of duration used in the other two tolerance models [3, 4] [2] ); consequently, the tolerance boundary was defined only up to 50 days duration in Eq. (10) of our article. Meade and colleagues note that beyond this duration, the boundary might rise rapidly as 2.158×T−3.5 Gy 10 . While this speculative extension is supported by theoretical considerations, fits to animal data, and observations of mucosal healing towards the end of long radiotherapy schedules [6] [7] [8] , it is not yet supported by clinical determinations of tolerability. Therefore, it should be viewed as hypothesis-generating at best, rather than as a firm indication of tolerability beyond 50 days duration. Thus, the ceilings obtained by Meade et al. for durations of 52 and 58 days using the extended model should be viewed with considerable caution.
Meade and colleagues noted further that a planned chemo-radiation schedule described by Bensadoun et al. [9] required lengthening when used clinically and thus might be considered intolerable. Delivery of 90.0 Gy 10 BED ck-RT over 46 days was planned, to which Meade et al. added a generic BED ck-chemo value of 5.1 Gy 10 to obtain a BED ck-tot of 95.1 Gy 10 . Since this lies below the Fen BED ck ceiling of 96.8 Gy 10 for 46 days duration, it was concluded that the model misclassifies the schedule as being tolerable. However, Meade et al. subsequently estimated a specific BED ck-chemo value of 11.7 Gy for the chemotherapy regimen used in this schedule, and adding this to the schedule's 90.0 Gy 10 BED ck-RT dose leads to a total BED ck-tot of 101.7 Gy, which lies above the ceiling defined by our model, correctly classifying the schedule as intolerable.
In summary, Meade and colleagues have conducted important new work analyzing the mucosal tolerability of HNSCC chemoradiotherapy schedules. Tolerability depends on treatment duration and BED ck-RT and BED ck-chemo doses, the use of biological response modifiers such as cetuximab, and probably also the spatial and temporal patterns of dose deposition [2, 10, 11] , and therefore its prediction is challenging. Consequently it is vital in such work that existing tolerability models are used precisely as they are defined, and only over the range of durations for which data support them, both to maximize the accuracy of predictive outcomes modelling and to allow significant differences between modelled and actual outcomes to be definitively attributed to effects not already included within the existing models.
